Why Cabaletta Bio, Inc.’s (CABA) Stock Is Up 5.67%
As of Wednesday, August 19, Cabaletta Bio, Inc.’s CABA share price has surged by 5.67%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Commentary & Analysis
Why Cabaletta Bio, Inc.’s (CABA) Stock Is Up 5.27%
As of Monday, August 17, Cabaletta Bio, Inc.’s CABA share price has surged by 5.27%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cabaletta Bio, Inc.’s (CABA) Stock Is Down 5.60%
As of Thursday, July 16, Cabaletta Bio, Inc.’s CABA share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cabaletta Bio, Inc.’s (CABA) Stock Is Down 5.04%
As of Monday, July 13, Cabaletta Bio, Inc.’s CABA share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Michael Rose
Why Cabaletta Bio, Inc.’s (CABA) Stock Is Down 7.38%
As of Friday, July 10, Cabaletta Bio, Inc.’s CABA share price has dipped by 7.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CABA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $530.7 | $292.6 | 37% |
|
| Shares Out (Mil) | 151.2 | 54.4 | 71% |
|
| Institutional Ownership | 98.8% | 93.2% | 82% |
|
| Float (Mil) | 141.5 | 40.2 | 68% |
|
| Beta | 3.25 | 0.94 | 98% |
|
| Avg Daily Volume (000s) | 5,004 | 544 | 92% |
|
| Price Change (52-week) |
98.1% | 59.7% | 90% |
|
| Growth | CABA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (38.2%) | (10.1%) | 10% |
|
| EPS (5yr) | (7.8%) | 16.0% | 23 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 7.6% | (15.6%) | 69% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.306) | ($1.356) | ($1.478) | |
| Month Ago EPS | ($0.315) | ($1.338) | ($1.420) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.315) | ($1.366) | ($1.468) | |
| Year/Year Chg | (9.5%) | (35.5%) | (33.8%) | |
| Financials | CABA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($181) | ($43) | 7% |
|
| EPS (TTM) | ($1.542) | ($1.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($154) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $80 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $294 | $164 | 30% |
|
| Valuation | CABA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.48 | 2.83 | 58% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CABA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (75.4%) | (47.5%) | 8% |
|
| ROE | (93.2%) | (55.0%) | 10% |
|
| Liabilities to Assets | 18.0% | 29.6% | 12% |
|
| F-Score | 2 | 3 | 7% |
|
Cabaletta Bio, Inc. did not pass any screens on 8/21/2026.
